Oculis (OCS) Euretina Innovation Spotlight (EIS) 2026 Presentation summary
Event summary combining transcript, slides, and related documents.
Euretina Innovation Spotlight (EIS) 2026 Presentation summary
1 Nov, 2026Pipeline and planned catalysts
Privosegtor is a neuroprotective candidate for optic neuritis, NAION and acute MS relapses; it received FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis.
Planned milestones: PIONEER-2 and PIONEER-3 trial initiations in Q4 2026; new IND submission for MS relapses in Q4 2026; PIONEER-1 enrollment completion in 2027.
Licaminlimab is in a genotype-based development program for TNFR1-mediated dry eye disease; PREDICT-1 topline results anticipated around year-end 2026.
ACUITY Phase 2 trial
Randomized, double-masked, placebo-controlled, multicenter, 6-month study; 36 patients randomized, with mITT population of 33, for unilateral demyelinating optic neuritis with symptom onset within 12 days.
Participants received once-daily IV privosegtor for 5 days at 2 or 3 mg/kg plus steroid, or placebo plus steroid; safety was the primary endpoint, with visual function, retinal anatomy and neurofilament light chain as secondary measures.
No adverse events led to drug withdrawal or study discontinuation, and no drug-related serious adverse events were reported; two unrelated SAEs were recorded, one in each treatment group.
ACUITY efficacy findings
The 3 mg/kg/day arm showed clinically meaningful, sustained low-contrast visual acuity improvement; reported changes were +18 ETDRS letters (p=0.004) and +15 letters (p=0.012).
GCIPL thickness results showed 43% greater preservation with privosegtor than placebo at Months 3 and 6; nominal p-values were 0.049 and 0.052, respectively.
Plasma neurofilament light chain results showed a 47% reduction; the reported nominal p-value was 0.046.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference